Due to the increasing number of patients with diabetes, a quick and simple screening test which can detect the early stages of diabetic retinopathy is highly valuable. Diabetic retinopathy is a feared disease as it can lead to complete blindness if left untreated and the symptoms are not easily detected by the patient. RetinaLyze’ s mission is to prevent vision loss. The detection of diabetic retinopathy in an early state is important as a quick and simple laser treatment can prevent the development of visual impairment and blindness. Early detection is now possible with the RetinaLyze software.
The RetinaLyze software was patented in 2002, in collaboration with Novo Nordisk A/S, one of the leading manufacturers of insulin in the world. The RetinaLyze software complies with the European Community Class I CE (according to the Medical Device Directive 93/42/EEC).
The RetinaLyze system is a vector-based algoritm and the patented invention relates to a method for assessing the presence or absence of retinal lesion(s) in an image. The RetinaLyze screening is an analysis performed on a Fundus Photo. The Fundus Photo is taken with a non-mydriatic Fundus Camera, connected to a digital system, which can store the digital images and upload them to the web application.
RetinaLyze offers immediate results. In less than a minute, the system gives a concise response regarding DR or AMD (Age-Related Macular Degeneration) as well as instructions on how to proceed. RetinaLyze allows the eye care professional to provide customers with results almost instantly, thereby achieving higher customer satisfaction. In addition to the contribution of clinical benefits, RetinaLyze is an excellent marketing tool. It has been shown to increase the flow of customers to the establishment by 20-30%.